Condition
Night Eating Syndrome
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 3 (1)
Trial Status
Completed3
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06588088Not ApplicableCompletedPrimary
Cardiorenal and Metabolic Effects of Nighttime Eating
NCT01401595Phase 3CompletedPrimary
Brain Imaging and Treatment Studies of the Night Eating Syndrome
NCT00636649Not ApplicableCompletedPrimary
Escitalopram Treatment of Night Eating Syndrome
Showing all 3 trials